Acadia Pharmaceuticals

Listing Websites about Acadia Pharmaceuticals

Filter Type:

Acadia Pharmaceuticals

(9 days ago) Acadia is trailblazing breakthroughs in neuroscience to elevate life. We are at the forefront of healthcare, fighting for breakthroughs in our science, our therapies and the way we work, but also in the lives of the people we serve. At Acadia, we are committed to our purpose: we fight disease so more you shines through.

Url: Visit Now

Category:  Health Detail Drugs


Acadia Pharmaceuticals - Wikipedia

(2 days ago) Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote

(6 days ago) Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

(6 days ago) ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals Stock Outlook Investment U

(3 days ago) Acadia Pharmaceuticals plans to submit an NDA for Trofinetide in mid-2022. ACP-044: Now in the earliest stages of clinical testing, ACP-044 is a novel orally-administered analgesic designed to treat postoperative and osteoarthritis pain. A Phase 2 study evaluating ACP-044 for postoperative pain treatment after bunionectomy surgery commenced in

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACAD Stock Price ACADIA Pharmaceuticals Inc. Stock Quote (U.S

(8 days ago) ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News

(2 days ago) Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Is ACADIA Pharmaceuticals Inc. (ACAD) a Winner in the Healthcare …

(Just Now) The 51 rating InvestorsObserver gives to ACADIA Pharmaceuticals Inc. ( ACAD) stock puts it near the top of the Healthcare sector. In addition to scoring higher than 75 percent of stocks in the Healthcare sector, ACAD’s 51 overall rating means the stock scores better than 51 of all stocks. ACAD has an Overall Score of 51.

Url: Visit Now

Category:  Pharmaceutical,  Health Detail Drugs


Why Acadia Pharmaceuticals Stock Is Rocketing Today

(3 days ago) Shares of Acadia Pharmaceuticals ( ACAD -5.92%) rose by as much as 19.2% in premarket trading Tuesday morning. The biotech's stock is taking flight today in response to a positive clinical readout

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Working at Acadia Pharmaceuticals Glassdoor

(9 days ago) Type: Company - Public (ACAD) Industry: Biotech & Pharmaceuticals. Revenue: $100 to $500 million (USD) Competitors: Biogen, Neurocrine Biosciences, Mirati Therapeutics. Create Comparison. Our care-ageous family aspires to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals (ACAD) - Forbes

(6 days ago) ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals Inc. - Crunchbase Company Profile

(2 days ago) Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Inc. Common Stock (ACAD)

(5 days ago) ACADIA Pharmaceuticals Inc. Common Stock (ACAD) Nasdaq Listed. Nasdaq 100. Data is currently not available. $26.00. -1.06 (-3.92%) DATA AS OF Apr 08, 2022. Add to Watchlist. Add to Portfolio.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals Reviews Glassdoor

(5 days ago) 19 Acadia Pharmaceuticals reviews. A free inside look at company reviews and salaries posted anonymously by employees.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals Inc. Company Profile San Diego, CA

(Just Now) Company Description: ACADIA Pharmaceuticals develops small molecule drugs for the treatment of central nervous system disorders. The biopharmaceutical company's pimavanserin (Nuplazid) was approved by the FDA in 2016 as a treatment for Parkinson's disease psychosis, a common development with the disease.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Furious Acadia takes shot at FDA, alleging sudden about-face in …

(7 days ago) Those are the words Acadia Pharmaceuticals had for an FDA rejection of its label expansion for Nuplazid, criticizing the agency for suddenly changing its mind despite a prior agreement that was

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Inc. Stock Forecast

(3 days ago) The ACADIA Pharmaceuticals Inc. stock price fell by -5.05% on the last day (Friday, 6th May 2022) from $18.83 to $17.88. and has now fallen 3 days in a row. During the day the stock fluctuated 5.55% from a day low at $17.65 to a day high of $18.63. The price has fallen in 6 of the last 10 days and is down by -12.48% for this period.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals Receives Complete Response Letter from …

(5 days ago) Media Contact: Acadia Pharmaceuticals Inc. Stephanie Fagan (858) 212-0534 [email protected]acadia-pharm.com Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 [email protected]acadia-pharm.com

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider James …

(7 days ago) On Wednesday, February 23rd, James Kihara sold 359 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $23.80, for a total value of $8,544.20. ACAD traded down $2

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Why Acadia Pharmaceuticals Stock Is Crashing Today - MSN

(4 days ago) Shares of the mid-cap biopharma Acadia Pharmaceuticals (NASDAQ: ACAD) fell by as much as 44% in pre-market trading Tuesday morning. The drugmaker's stock is crashing today in response to a

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals Announces August 4, 2022 Action Date for

(6 days ago) Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Adm

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals

(2 days ago) ACADIA Pharmaceuticals (NASDAQ: ACAD) has observed the following analyst ratings within the last quarter: These 7 analysts have an average price target of $31.14 versus the current price of ACADIA

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Stock Forecast & Price Targets

(5 days ago) Analyst Price Target on ACAD. Based on 16 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $29.07 with a high forecast of $37.00 and a low forecast of $20.00. The average price target represents a 81.35% change from the last price of $16.03.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACAD Stock News ACADIA PHARMACEUTICALS Stock Price …

(3 days ago) ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACAD: ACADIA Pharmaceuticals Inc - Stock Price, Quote and News …

(2 days ago) Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Inc. Common Stock (ACAD)

(Just Now) ACADIA Pharmaceuticals Inc. Common Stock (ACAD) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Stock Competitors - MarketBeat

(5 days ago) ACADIA Pharmaceuticals has a consensus price target of $29.45, suggesting a potential upside of 50.73%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Should You Buy ACADIA Pharmaceuticals Stock At $22?

(8 days ago) We believe that ACADIA Pharmaceuticals stock (NASDAQ NDAQ -1.7%: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Acadia Pharmaceuticals AMGA

(8 days ago) Email: [email protected]acadia-pharm.com About: Acadia is trailblazing breakthroughs in neuroscience to bring vital solutions to those who need them most. The team has spent the last 25 years working at the forefront of healthcare, focusing on central nervous disorders and early-stage clinical research.

Url: Visit Now

Category:  Health Detail Drugs


ACADIA Pharmaceuticals Inc (ACAD) Quote - XNAS Morningstar

(Just Now) Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals : DRP PDUFA Update MarketScreener

(8 days ago) ACADIA Pharmaceuticals Inc. published this content on 05 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 April 2021 12:09:07 UTC.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ACADIA Pharmaceuticals Inc.: Rosen Law

(1 days ago) ACADIA Pharmaceuticals Inc. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive (the “Class Period”).

Url: Visit Now

Category:  Pharmaceutical Detail Drugs

Popular Searched

 › Cyp2d6 substrates drug list

 › Kaiser pharmacy mercury way hours

 › Cms managed care manual chapter 6

 › Georgia family medicine watkinsville ga

 › Carepass coupon code cvs

 › Kaiser pharmacy mercury way hours

 › Fort hood pharmacy formulary

 › Biggest pharmacy benefit managers

 › Myuhcmedicare.com hwp sign in

 › Cvs caremark opt out of mail order

Recently Searched

 › Drug development process us

 › Trazodone drug test positive

 › Telehealth cpt and hcpcs codes

 › Investigational new drug number lookup

 › Bakersfield heart hospital sold

 › Wisconsin seniorcare drug formulary

 › Goodrx compare drug prices

 › Optumrx approved pharmacy locations

 › Finger lakes health employment

 › Pharmaceutical manufacturing companies in india

FAQ about Acadia Pharmaceuticals

What does Acadia Pharmaceuticals do?

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning."

What is the mailing address for Acadia Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at [email protected], or via fax at 858-558-2872.

Is the Acadia Pharmaceuticals (Acadia) stock falling?

The ACADIA Pharmaceuticals Inc. stock price fell by -1.44% on the last day (Friday, 21st Jan 2022) from $21.49 to $21.18. and has now fallen 3 days in a row. During the day the stock fluctuated 5.33% from a day low at $20.94 to a day high of $22.05.

What is the Acadia Pharmaceuticals StoryCorps campaign?

In collaboration with StoryCorps, the campaign provides the Parkinson’s disease community a unique forum to record, share and archive their personal stories, in both Spanish and English, while also see ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021.